Wait goes on further for Endo over FDA lawsuit

Ireland-incorporated drugmaker Endo International (Nasdaq: ENDP) has announced that the US Food and Drug Administration (FDA) has requested a further stay of Endo's ongoing litigation against the FDA through March 15.

The suit was first filed in October 2017 by two of Endo’s subsidiaries in the US District Court for the District of Columbia.

They sought a declaration that the FDA's interim policy on bulk compounding of numerous products, including vasopressin, was unlawful under the Drug Quality and Security Act of 2013 (DQSA) amendments to the Federal Food, Drug, and Cosmetic Act (FDCA).